INTRODUCTION

Modelling the clinical and economic implications of galantamine in the treatment of mild to moderate Alzheimer’s disease in Germany.

METHODS

An economic model using a Markov state transition approach was created to perform analyses from the perspective of German patients, payers, and society.

RESULTS

The results of the one-way sensitivity analyses based on the comparison of galantamine vs. no-drug treatment are shown in Figure 3. The model was run for a 10-year model time horizon.

CONCLUSION

The present analysis suggests that galantamine may only delay clinical benefit in terms of delaying disease progression while resulting in an increase in total costs for patients with Alzheimer’s disease. This result may not be generalizable to other settings or other patient populations.

REFERENCES